- Previous Close
8.91 - Open
9.05 - Bid 8.61 x 100
- Ask 9.16 x 100
- Day's Range
8.94 - 9.05 - 52 Week Range
7.26 - 25.19 - Volume
600 - Avg. Volume
258,352 - Market Cap (intraday)
394.472M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.45 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
38.50
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cystic fibrosis (CF). It develops nucleotide-binding domain 1 (NBD1) stabilizers that normalize CFTR function for CF patients; Galicaftor (SION-2222) and SION-2851; SION-109, an ICL4-directed CFTR corrector; and Navocaftor (SION-3067), a potentiator. Sionna Therapeutics, Inc. formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
www.sionnatx.comRecent News: SION
View MorePerformance Overview: SION
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SION
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SION
View MoreValuation Measures
Market Cap
393.15M
Enterprise Value
585.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.10%
Return on Equity (ttm)
-61.44%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-61.69M
Diluted EPS (ttm)
-1.45
Balance Sheet and Cash Flow
Total Cash (mrq)
147.54M
Total Debt/Equity (mrq)
5.85%
Levered Free Cash Flow (ttm)
-40.48M